Cat. No. 1813
Alternative Name: Indirubin-3'-monoxime
Chemical Name: 3-[1,3-Dihydro-3-(hydroxyimino)-2H-
Biological ActivityProtein kinase inhibitor; inhibits cyclin-dependent kinases (IC50 = 0.18 - 3.33 μM) and GSK-3β (IC50 = 0.19 μM). Inhibits CDK5- and GSK-3β-mediated tau phosphorylation, a process over-active in Alzheimer disease states. Also inhibits AMPK, LCK and SGK. Induces cell cycle arrest and inhibits cell proliferation.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Hoessel et al (1999) Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat.Cell.Biol. 1 60. PMID: 10559866.
Leclerc et al (2001) Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. J.Biol.Chem. 276 251. PMID: 11013232.
Bain et al (2003) The specificities of protein kinase inhibitors: an update. Biochem.J. 371 199. PMID: 12534346.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Indirubin-3'-oxime, supplier, Protein, kinase, GSK-3β, GSK-3beta, inhibits, inhibitors, kinases, Cyclin-dependent, Induces, cell, cycle, arrest, antiproliferative, Broad, Spectrum, GSK, Glycogen, Synthase, 3, Cdk, Cyclin-Dependent, Carbohydrate, Metabolism, Cell, Cycle, Indirubin-3-oxime, Indirubin-3-monoxime
Find multiple products by catalog number
New Products in this Area
Glucokinase activatorMRT 67307 dihydrochloride
Salt inducible kinase (SIK) inhibitorLDN 209929 dihydrochloride
Potent and selective haspin kinase inhibitorRKI 1447 dihydrochloride
Potent and selective ROCK inhibitor; antitumorLIMKi 3
Potent LIM kinase inhibitor; antitumorFRAX 486
Potent p21-activated kinase (PAK) inhibitor; brain penetrant and orally bioavailableBIX 02189
Selective MEK5 and ERK5 inhibitorTC Mps1 12
Potent and selective monopolar spindle 1 (Mps1) kinase inhibitor; orally activeGSK 2606414
Potent and selective PERK inhibitor; orally bioavailableAZ 20
Potent and selective ATR kinase inhibitor; antitumorAZD 7762 hydrochloride
Potent and selective ATP-competitive inhibitor of Chk1 and Chk2PHT 427
Dual Akt and PDK1 inhibitor; antitumorML 786 dihydrochloride
Potent Raf kinase inhibitor; orally bioavailableSenexin A
Cyclin-dependent kinase 8 (cdk8) inhibitorXL 388
Potent and selective mTOR inhibitor; antitumorPS 1145 dihydrochloride
Selective IKK inhibitor; orally activeRSVA 405
AMPK activatorAtiprimod dihydrochloride
November 15 - 19, 2014
Washington D.C., USA